Fuzhou Quanye Economic Technology

Fuzhou Quanye Economic Technology is a Chinese biotechnology company focused on the development of innovative metabolic and endocrine therapies. The company specializes in the research of multi-receptor agonists, particularly targeting GLP-1, GIP, and glucagon receptors for the treatment of type 2 diabetes and obesity. Their pipeline includes several early-stage candidates designed to improve glycemic control and promote weight loss. Fuzhou Quanye operates primarily within the domestic Chinese market, leveraging local R&D expertise to advance its metabolic disease portfolio. The company aims to provide high-quality, cost-effective therapeutic options for chronic metabolic conditions.